Kalshi introduces prediction markets for clinical trials, FDA approvals
Prediction markets have permeated the worlds of sports, politics, and reality television shows. Now, the biopharma industry could be next.
On Thursday, Kalshi, one of the world’s largest prediction market exchanges, said it will start taking bets on clinical trials and regulatory approvals.
It’s starting with a small number of markets chosen in collaboration with its partner, AppliedXL, a tech company that monitors and predicts the outcomes of clinical trials.
Your morning rundown of the science, politics, and money driving biotech today
STAT Plus: The end for GSK’s chronic cough treatment By Meghana Keshavan
Biotech Biotech July 17, 2026 STAT Plus: Can ultrasound unlock the power of gene therapy? A startup makes big claims By Jason Mast
The Readout The Readout July 16, 2026 STAT Plus: FDA approves Merck’s oral PCSK9 drug, a first By Meghana Keshavan and Matthew Herper
Biotech Biotech July 16, 2026 STAT Plus: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley By Adam Feuerstein
Adam's Biotech Scorecard Adam's Biotech Scorecard July 16, 2026 STAT Plus: Amylyx nears pivotal endocrine drug study readout By Adam Feuerstein
A decade of reporting from the frontiers of health and medicine
Original Source
This content was distilled for a focused reading experience. All rights belong to STAT.
Read original publication